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Blood histamine levels (BHL) in patients with malignant lymphomas - Hodgkin's 
disease (HD) and non-Hodgkin's lymphomas (NHL) as well as with chronic lymphocytic 
leukenia (CLL) were studied in the active phase of the diseases and during remission after 
treatment. BHL were significantly decreased by 2,5-fold in HD patients in the active phase 
as compared to the controls. After treatment and during remission BHL normalized. It was 
found out that according to the calculated correlation R and determination (D) coefficients 
of BHL with the obligatory indices for biological activity in HD (ESR, fibrinogen, serum 
iron, al-protein fraction), the most informative criterion for the active phase was ESR 
(R=0,99, D=98 %)followedbyBHL(R=-0,89, D=79%), andBHLduring remission (R=0,87, 
D=75 %). In NHL patients, no significant differences in BHL in comparison to clinically 
healthy persons were established independently of the process activity and grade of malig­
nancy. In patients with CLL, however, BHL were statistically significantly (p < 0,01) el­
evated by 45,8 % during the active stage compared with the control group. A significant 
correlation was found between the BHL and leukocyte counts in the active phase of the 
disease (rs = 0,71, p < 0,001). BHL normalized during remission. Therefore, BHL can be 
used as an additional criterion for the evaluation of the biological activity and remission in 
HD patients. 
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lymphoprol i ferat ive disorders are 
scarce. To our best knowledge, such 
studies related to Hodgkin's disease 
( H D ) have not been reported in the 
specialised literature available, and 
there are only a few related to non-
Hodgkin 's lymphomas ( N H L ) ( 8 ) . 
There are also very few reports on 
chronic lymphocytic leukemia ( C L L ) in 
which, however, the disease phase when 
the studies are conducted is not speci­
fied (3,11). 
Changes in blood histamine lev­
els have been established in a number 
of stem cell - myeloproliferative disor­
ders such as chronic myelogenous leu­
kemia (2-6,12) and polycythemia vera 
(1.2,6,7,11). However, the studies of 
blood histamine leve ls in 
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A. Belcheva 
In this study we aimed at exam­
ining the clinical significance of blood 
histamine level in patients with H D , 
N H L and C L L in the active phase of 
the diseases and during remission fol­
lowing the respective treatment as well 
as at seeking for a correlation of this 
index wi th b io logica l and 
haematological indices of biological 
activity in the above diseases. 
MATERIAL AND METHODS 
Fourty-three patients with H D 
(mean age of 41,8 years), 30 patients 
with N H L (mean age of 36,6 years), and 
35 patients with C L L (mean age of 45,2 
years) were included in this trial. The 
patients were treated according to the 
conventional regimens. They were in­
vestigated in the active phase of the dis­
ease and during remission after the cor­
responding treatment for the following 
indices: blood histamine in all patients, 
spectrofluorimentrically after Lorenz et 
al. (9); indices for biological activity in 
patients wi th H D : E S R (after 
Westergren); fibrinogen (after Podmor 
D A ) ; alpha2-protein fraction (electro-
phoretically); serum iron (by bato-
phenantroline method); leukocyte count 
in C L L . T h e same indices were 
investigafecl monitored in 30 age- and 
sex-matched healthy persons (mean age 
of 35,5 years). 
In order to measure the data ob­
jectively the variation, correlation, and 
regression statistical analyses were 
used. 
RESULTS AND DISCUSSION 
Blood histamine levels in pa­
tients with H D in the active phase were 
about 2,5-fold lower than in the group 
of healthy controls (0,030 ± 0,002 pg/ 
ml vs 0,072 ± 0,002 Mg/ml). During re­
mission after treatment the histamine 
levels increased reaching up to 0,077 
± 0,006 Mg/ml. We used the probability 
assessment method for the permission 
ability of a criterion to determine the 
differentiation value of blood histamine 
index for the states of activity and re-
Table 1 
Mean values of the indices for biological activity in HD patients 
Indices HD patients Controls 
active phase remission 
ESR (mm) 66,54 ± 4,95* 24,67 ± 3,36* 8,60 ± 0,94 
Fibrinogen 6,93 ± 0,66* 3,09 ±0,14 2,93 ±0,14 
a 2- fraction (g/l) 0,19 ±0 ,01* 0,13 ±0,05 0,09 ± 0,01 
Serum iron (Ц/1) 8,66 ± 1,14* 13,57 ±0 ,99 15,27 ± 1,26 
B H L (ц/ml) 0,030 ± 0,002* 0,077 ±0,006 0,072 ±0,002 
"p< 0,001 
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mission in H D - 0,040 vg/m\. 
In patients in active phase out 
of the obligatory indices for biological 
activity (10) we found out that as com­
pared to the control group the follow­
ing values were statistically signifi­
cantly increased: E S R , fibrinogen and 
alphaz-protein fraction, and the values 
of serum iron were significantly de­
creased. During remission only the E S R 
values remained significantly higher 
(Table 1). B y means of regression mod­
els the coefficients of correlation and 
determination were calculated. The cor-
Table 2 
irrelation coefficients (R) of criteria for 
relation coefficients provide informa­
tion about the normal relation and de­
pendence of the values of the respec­
tive index on the disease phase. The 
correlation coefficient is a measurement 
of the interaction power between phe­
nomena and ranges from 0 to 1. The 
calculation of the correlation coeffi­
cients indicate that during the active 
phase E S R is the most informative ( R l 
= 0,99, p < 0,001) followed by the his­
tamine level ( R l = 0,89, p < 0,001). For 
remission the histamine level is the 
most informative ((R2 = 0,87, p < 0,01) 
(Table 2). 
biological activity in HD 
ndices active phase Ri remission R2 
R (mm) 
rinogen 
a 2-fraction (g/l) 
Serum iron (ц/1) 













 what percentage of the changes in 
the investigated parameters is deter­
mined by the disease process. The es­
tablished values show that the highest 
degree of informativeness in the activ­
ity phase is borne by the indices E S R 
( D l = 98,01 % ) and histamine level ( D l 
= 79,21 % ) and for remission - hista­
mine level (D2 = 75,69 % ) and with f i ­
brinogen (D2 = 62,41 % ) (Table 3). 
Table 3 
Determination coefficients (D) of criteria for biological activity in HD 
Jndices active phase Di (%) remission D 2 (%) 
ESR (MM) 98,01 20,35 
Fibrinogen 66,23 62,41 
a 2- fraction (g/l) 78,51 17,08 
Serum iron (ц/1) 51,84 
v28,09 




The mean blood histamine lev-
els in patients with N H L in relapse was 
0,087 ±0 ,012 Mg/ml. The difference in 
comparisson to the control group is not 
statistically significant. No difference 
in blood histamine levels was estab-
lished in patients with high grade N H L 
malignancy (0,086 ± 0,023 Mg/ml) and 
those with low grade N H L (0,087 ± 
0,008 Mg/ml). After treatment the mean 
blood histamine levels in patients with 
N H L was 0,073 ± 0,01 mkg/ml which 
approximated closely the control val-
ues. 
In patients with C L L during ac-
tive disease phase the blood histamine 
level was 0,110 ± 0,015 Mg/ml. The 
elevabion by 45,8 % as compared to the 
healthy control group was statistically 
significant (p < 0,01). During remission 
as a result of the treatment the mean 
histamine values decreased to 0,079 ± 
0,011 Mg/ml. The mean leukocyte count 
in patients with C L L in the active phase 
was 89,7 ± 15,0xl0 9 / l which was by 
about 17 times higher than the mean 
values in the control group - 5,3 ± 
0 ,15xl0 9 / l . 
In patients during remission the 
leukocyte count decreases, the mean 
value of 19,8 ± 6,9x10 9/l being statisti-
cally significantly (p < 0,01) lower than 
that in the active phase. Nevertheless, 
it is about twice as high as of the refer-
ence values for this index. During the 
active phase of the disease a strong sta-
t i s t i ca l ly s igni f icant correlation 
(Spearman's rank correlation coeffi-
cient r s = 0,71; p < 0,001) was estab-
lished between blood histamine levels 
and the leukocyte count. During remis-
sion this correlation is not statistically 
significant. 
The results obtained point to the 
following conclusions: 
1. In patients with H D the blood 
histamine levels can be used as an ad-
ditional criterion for assessing the states 
of biological activity and remission re-
sulting from effective treatment. 
2. In patients with C L L the 
changes in the leukocyte count which 
indicate the disease activity affect the 
changes in histamine levels which sug-
gests that blood histamine level can be 
used as an additional criterion for dis-
ease activity assessment. 
3. In patients with N H L blood 
histamine levels are a not an informa-
tive index neither for process activity 
assessment, nor for the grade of disease 
malignancy. 
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Ниво на хистамина в кръвта при болни с лимфопролиферативни 
заболявания 
А. Белчева 
Катедра по фармакология, Медицински университет-Варна 
Резюме: Нивото на хистамина в кръвта (НКХ) при болни с малигнени лимфоми -
болеет на Ходжкин (БХ) и не-Ходжкинови лимфоми (НХЛ), и с хронична лимфоцитна 
левкемия (ХЛЛ) е проследено в активна фаза на заболяванията и след лечение. Данните 
показват, че НКХ при болни с БХ в активна фаза е статистически значимо намалено 
2,5 пъти в сравнение с това при контролна група здрави лица. След лечение и в ремисия 
НКХ се нормализира. Изчислените коефиценти на корелация (R) и детерминация (D) 
на НКХ със задъжителните показатели за биологична активност при БХ (СУЕ, 
фибриноген, серумно желязо, 2-протеинова фракция) показват, че най-информативен 
за активност на процеса е СУЕ (R = 0,99, D = 98 % ) , следван от НХК (R = -0, 89, D = 79 
% ) , а за ремисия - НХК (R = 0,87, D = 75 % ) . НХК при болни с НХЛ не се различава 
значимо от това на контролната група, независимо от активността на процеса и 
степента на малигненост. При болни с ХЛЛ нивото на хистамина е с 45,8 % (р < 0,01) 
по-високо от това при здравите лица. Установена е значима корелативна зависимост 
на НХК с броя на левкоцитите (r s = 0,71, р < 0,001). При ремисия НХК се нормализира. 
Предлага се НХК като допълнителен критерий за преценка на състоянията на 
биологична активност и ремисия при болни с БХ. 
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